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History-Adjusted Marginal Structural Models
to Estimate Time-Varying Effect Modification
Maya L. Petersen, Steven G. Deeks, Jeffrey N. Martin, and Mark J. van der Laan

Abstract

Much of epidemiology and clinical medicine is focused on the estimation of
treatments or interventions administered over time. In such settings of longitudinal treatment, time-dependent confounding is often an important source of bias.
Marginal structural models are a powerful tool for estimating the causal effect of
a treatment using observational data, particularly when time-dependent confounding is present. Recent statistical work presented a generalization of marginal structural models, called history-adjusted marginal structural models. Unlike standard
marginal structural models, history-adjusted marginal structural models can be
used to estimate modification of treatment effects by time-varying covariates. Estimation of time-dependent causal effect modification is frequently of great practical relevance. For example, clinical researchers are often interested in how the
prognostic significance of a biomarker for treatment response can change over
time. This article provides a practical introduction to the implementation and
interpretation of history-adjusted marginal structural models. The method is illustrated using a clinical question drawn from the treatment of HIV infection. Observational cohort data from San Francisco, California, collected between 2000 and
2004, are used to estimate the effect of time until switching antiretroviral therapy
regimen among patients receiving a non-suppressive regimen, and how this effect
differs depending on CD4 T cell count.

INTRODUCTION
Dynamic treatment regimens are decision rules for altering treatment in response
to changes in patient or pathogen characteristics. Such dynamic decision-making is
central to the practice of medicine; clinicians select a future treatment plan that is
expected to optimize a patient's long-term outcome, then modify this treatment plan over
time in response to changes in disease progression. For example, patient risk factors and
sequential measurements of blood pressure inform when antihypertensive medication is
initiated. Similarly, the dose of antidepressant medication is often modified in response to
changes in patient symptoms and side effects. And, as will be described here, the decision
to switch antiretroviral therapy regimen for an Human Immunodeficiency Virus (HIV)infected patient is based on the virologic and immunologic response to treatment, as well
as side effects and other factors.
Despite the crucial and ubiquitous role of dynamic decision making in medicine,
rigorous identification of candidate dynamic treatment regimens and evaluation of their
effectiveness remains relatively rare. Randomized controlled trials can be used to
compare candidate dynamic treatment regimens; however these trials do not themselves
identify the decision rules to be compared. We suggest that observational data provide a
rich source for identifying dynamic treatment regimens expected to optimize patient
outcome. We introduce a new methodology, history-adjusted marginal structural models
(HA-MSM) (1), which directly identifies a specific type of optimal dynamic treatment
regimen using observational data.
HA-MSM generalize marginal structural models (MSM), introduced by Robins,
(2-4). MSM are a powerful statistical tool for causal inference. Epidemiological and
clinical research often relies on longitudinal treatment status and covariate data. When
treatment status changes over time, conventional analytic approaches (such as standard
multivariable regression methods) often fail to provide valid causal inference about the
effect of treatment. Marginal structural models address this well-recognized problem of
time-dependent confounding.
While MSM address confounding by time-dependent covariates, to date they have
been restricted to the estimation of effect modification by baseline covariates only. Thus
it has been possible to use this methodology to address questions such as "What is the
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effect of a treatment and how does it differ between study members with different
covariate values at entry to the study?", but not "How does the effect of a treatment differ
as a result of changing values of a covariate over the course of the study?". As a result,
MSM have not been applied to identify optimal dynamic treatment regimens.
As will be outlined here, HA-MSM use the identical causal framework as
standard MSM, but unlike MSM, can be used to identify a rule for making treatment
decisions over time, based on time-varying covariates, that represents a specific type of
optimal dynamic treatment regimen. This dynamic treatment regimen corresponds closely
to the needs of clinical practitioners, in that it allows a practitioner to use a patient's most
recent measured covariates to update, at each patient visit, the future treatment plan that
will maximize the patient's expected long-term outcome.
This paper provides a practical introduction to HA-MSM; the formal statistical
theory and assumptions are presented in (1). We illustrate our methodology with an
example drawn from the treatment of HIV using antiretroviral therapy (ART).
ANTIRETOVIRAL THERAPY FOR THE TREQTMENT OF HIV INFECTION:
WHEN TO SWITCH?
HIV evolves rapidly in the presence of a selective pressure. This leads to the
accumulation of mutations that confer "resistance" to antiretroviral drugs. The optimal
manner to avoid the rapid emergence of resistance-associated mutations is therefore to
completely suppress viral replication. This can be achieved in many patients with
standard three-drug combination regimens (5). However, a substantial proportion of
treated patients fail to achieve complete viral suppression. Such patients are often
switched to a new regimen, but this can lead to the use of all available therapeutic
options. Since many patients with incomplete viral suppression continue to do well
immunologically (and therefore clinically) (6-8), many clinicians choose not to switch to
a new regimen as long as CD4 T cell counts remain elevated. Hence, clinicians are often
faced with a dilemma in patients with detectable viremia on therapy: should they switch
therapy as soon as possible, thereby risking using up all drugs quickly and exposing
patients to increasingly complicated and potentially toxic regimens? Or should they
maintain patients on a partially suppressive regimen as long as they are doing well
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immunologically and clinically, even though this approach will allow the ongoing
accumulation of drug-resistance mutations that can limit future therapeutic options? (For
a review of this issue, see Deeks (9).)
In this paper, we estimate the effect of non-suppressive therapy on future CD4 T
cell count, and estimate how this outcome differs depending on a patient's current CD4 T
cell count, and time spent on non-suppressive therapy. Based on these estimates, we
identify a rule for deciding when to switch to a new antiretroviral therapy that will
maximize the patient's expected CD4 T cell count in the future. Data for these analyses
are drawn from the Study on the Consequences of the Protease Inhibitor Era (SCOPE), an
observational cohort of HIV-infected patients in San Francisco. Participants are seen at 4month intervals. At each visit, they complete interviewer- and self-administered
questionnaires examining domains including socioeconomic status (housing, income,
employment), antiretroviral medication use and adherence, occurrence of opportunistic
infection or malignancy, and recreational drug use. Plasma HIV RNA levels and
CD4/CD8 T cell counts are measured at each visit, as well as between visits according to
physician discretion. Importantly, decisions as to when and how to modify therapy are
made by primary care providers based on standard of care.
For our current analysis, we retrospectively identified subjects from SCOPE who
experienced virologic failure while being observed in this study.

Subjects became

eligible for our analyses (t=0) if they failed to achieve an undetectable HIV RNA levels
(< 75 copies RNA/mL) by week 24 on a new regimen, or if they rebounded from an
undetectable level. The exposure of interest was time until switching to a new therapy.
This can be summarized as a binary variable at each time point, indicating whether or not
a subject has switched off of his or her original non-suppressive ART regimen. We only
allowed subjects to switch once in our analyses. The method can be easily extended,
however, to encompass more complex treatment patterns.
In the sections which follow, we rely on this data structure to illustrate our
methodology. In the final section, we present the results of our analyses.
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THE COUNTERFACTUAL FRAMEWORK
The causal effect of a treatment on an individual can be defined as the difference
in the individual's outcome with and without the treatment. Such outcomes are termed
counterfactual because only one is observed for each individual. MSM are models of how
the population distribution of these counterfactual outcomes changes as a result of
changes in treatment.
We begin by introducing some standard notation. Treatment over the course of
the study (t=0,...,K) is denoted A( K ) = ( A(0),..., A( K )) , and covariates are denoted

L( K + 1) , where treatment occurs after covariates at a given time point, and K+1 is the
end of follow-up. In our HIV example, A(K ) is a vector of binary variables, consisting

of one for each time point until a subject switches therapy, and zero thereafter. For each
possible time until switching, L a ( K + 1) denotes the counterfactual CD4 T cell counts
and other covariates over time that would have been observed if the subject had switched
therapy at the time implied by A = a . The outcome for a given time point t is the
counterfactual CD4 T cell count measured 8 months in the future under the switching
time indicated by a , denoted Ya (t + 8) .
If we observed the counterfactual CD4 T cell counts for each individual under
each possible switch time, we could estimate the causal effect of waiting to switch
therapy by simply comparing the counterfactual outcomes under different switch times.
However, we only observe the CD4 T cell counts for each individual under a single (nonrandom) switch time. As a result, in order to estimate the effect of time until switching
therapy on CD4 T cell count using the observed data, we must assume that the covariates
we measured are sufficient to control for confounding. For example, within strata defined
by our measured confounders, there must be no unmeasured variables that predict, at any
time point, both probability of switching treatment and also CD4 T cell count 8 months in
the future.
Under this assumption, we could use standard MSM to ask: "At baseline (when
virologic failure occurs), how does time until switching to a new regimen affect CD4 T
cell count 8 months later? How does this effect differ depending on a patient's CD4 T cell
count at baseline?" However, an MSM assumed at a single time point does not allow us
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to estimate how the effect of future non-suppressive therapy may change as a result of
changes in a patient's CD4 T cell count, or how this information should be used to decide
when to switch a patient to a new ART regimen. HA-MSM directly address these
questions.
HISTORY-ADJUSTED MARGINAL STRUCTURAL MODELS
HA-MSM rely on the identical causal framework as standard MSM, but estimate
a different parameter of interest. HA-MSM assume a standard MSM at each time point
during the study, which models counterfactual outcomes indexed by treatment that occurs
after that time point, conditional on some subset of the observed history up till that time
point. In addition, HA-MSM allow us to assume a common model across time points. In
other words, HA-MSM model some parameter of the counterfactual outcome if the study
population were to follow their observed treatment history up till time j, followed by a
specified counterfactual future treatment history until outcome is measured, conditional
on a subset of (possibly time-varying) covariates and/or treatment history measured
before time j. In this article, we will focus on HA-MSM concerned with the mean of
these counterfactual outcomes; however, the same framework can be readily adopted to
model any other parameter.
We denote a future longitudinal treatment regimen, beginning at time j and
continuing until the outcome is measured m time points later, as
a ( j , j + m − 1) ≡ (a ( j ), a ( j + 1),...a ( j + m − 1)) , for j = 0,..., K + 1 − m . The effect

modifiers of interest are denoted V ( j ) ⊂ ( L( j ), A( j − 1)) , a subset of a subject's treatment
and covariate history up till time j. For each time point in the study for which the
outcome m time points later is defined, HA-MSM model the expectation of the
counterfactual outcome Y A( j −1),a ( j , j + m −1) ( j + m) , conditional on V(j), under each possible
future treatment regimen. Thus, HA-MSM are concerned with estimation of the
following parameter: E (Y A( j −1),a ( j , j + m −1) ( j + m) | V ( j )) , where j=0,…,K+1-m.
Applied to our example, future antiretroviral treatment from time j until the
outcome is measured, denoted a ( j , j + m − 1) , consists of a vector of counterfactual
treatment decisions a(j),…a(j+m-1) , where a(t)=0 if a subject has switched treatment at
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or before time t, and otherwise a(t)=1. This vector of future treatment decisions exists for
each subject beginning at each time point j=0,…,K+1-m. We summarize a ( j , j + m − 1)
as c( j ) ≡ ∑l = j a(l ) , which represents the future time (beginning at time point j) that the
j + m −1

subject will spend on his/her original failing therapy before either switching or the
outcome is measured. The current CD4 T cell count at time j is denoted CD4(j)=S(j), a
subset of the full covariate history measured over time, L( j ) . For each time point j, we
are interested in the mean counterfactual CD4 T cell count m=8 months later among
individuals who have not yet switched therapy, if they were to switch therapy at a
specified counterfactual time after j.
To address this question, we might assume the following model:
E (Y A( j −1),c ( j ) ( j + 8) | A( j − 1), CD 4( j )) = I ( A( j − 1) = 1) ×
( β 0 + β 1c( j ) + β 2 CD 4( j ) + β 3 j + β 4 c( j ) × CD 4( j ) + β 5 c( j ) × j )

(1)

j = 0,..., K + 1 − 8 .
In other words, we might assume that, among individuals who have not yet
switched treatment (A(j-1)=1), counterfactual CD4 T cell count 8 months later depends
on additional time until switching (c(j)), but the magnitude of this effect differs
depending on the duration a patient has already spent on non-suppressive therapy (j) and
current CD4 T cell count (CD4(j)).
This model allows us to estimate the effect of each additional month until
switching to a new therapy on CD4 T cell count 8 months later, among patients who have
been on their current non-suppressive therapy for different durations and have different
current CD4 T cell counts. For example, by testing whether β 4 = 0 we are testing the
hypothesis that a subject's current CD4 T cell count modifies the effect of future time
until switching.
INVERSE PROBABILTIY OF TREATMENT WEIGHTED ESTIMATION
Several HA-MSM estimators are available; here, we focus on the inverse
probability of treatment weighted (IPTW) estimator, which can be implemented using
standard software. The IPTW estimator can be understood as simply a weighted least
squares estimator. For each time point j in the study, each subject receives a weight
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which is informally the inverse of the subject's probability of receiving the treatment that
he or she actually received, from time point j until the outcome is measured. If a subject
has a longitudinal treatment regimen beginning at time point j that occurs frequently in
the data among subjects with his covariate and treatment history, he receives a small jspecific weight. In contrast, if the subject has an unusual longitudinal treatment regimen
given his covariates, the subject will receive a large weight. In our HIV example, patients
whose CD4 T cell counts have recently declined are more likely to switch therapy. A
subject that did not switch therapy despite a recent decline in CD4 T cell count would
thus have a small predicted probability of receiving her observed treatment, and receive a
large weight.
The first step in implementing the IPTW estimator is to model the treatment
mechanism, or fit a predictive model of treatment at each time point t, given the
observed past up till that time point: g ( A(t ) | A(t − 1), L(t )) , t = 0,..., K . For example,
we model the treatment decision (switch therapy or not) made at every time point t using
logistic regression. A simple model of the treatment mechanism might be:
logit( A(t ) | A(t − 1 = 1, CD 4(t )) = θ 0 + θ1CD 4(t ), t = 0,..., K ,

(2)

where CD4(t) is CD4 T cell count at time t. Recall that once a subject switches, he/she is
no longer at risk of switching in the future. Thus, when fitting our model of the
probability of staying on therapy at a given time point (A(t)=1), we fit the model only
among subjects who have not already switched before that time point (A(t-1)=1).
For the IPTW estimator to be consistent, the estimate of the treatment mechanism
must be consistent and enough covariates must be included in the treatment model so that
outcome is independent of treatment assignment conditional on the variables in the model
(or in other words, there must not be additional confounders that do not appear in the
model of the treatment mechanism).
For each time point j=0,...,K+1-m, the model of the treatment mechanism
(equation 2) is used to estimate the denominator of the j-specific weight:
j + m −1

∏ g ( A(l ) | A(l − 1), L(l ))
l= j

For subjects who do not switch therapy before the outcome is measured m months later,
the denominator of the j-specific weight is
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j + m −1

∏ P( A(l ) = 1 | A(l − 1) = 1, CD 4(l ))
l= j

For subjects who have not switched therapy by time j, but who switch at some point
T=j+C(j) before the outcome is measured (C(j)< m), the denominator of the j-specific
weight is
T −1

(1 − P( A(T ) = 1 | A(T − 1) = 1, CD 4(T )))∏ P( A(l ) = 1 | A(l − 1) = 1, CD 4(l ))
l= j

Recall that subjects who have already switched therapy by time j do not contribute to our
counterfactuals of interest.
The weight is then calculated as the inverse of the denominator. Note that the
same subject will have a separate weight for each time point j in the study, with
denominators corresponding to the probability that the subject received his/her observed
treatment from that time point j until the outcome is measured. Once each subject has
been assigned a set of K+1-m weights, a weighted least squares regression is run using
standard software, with each subject contributing K+1-m weighted lines of data.
THE HA-MSM DYNAMIC TREATMENT REGIMEN
For each time point during the study, HA-MSM identify the future static
treatment regimen that will maximize the expectation of the outcome, given treatment
history and covariates of interest up till that time point. Recall that a static treatment
regimen allows treatment to change over time, but not in response to changing patient
covariates. In our example, model 1 allows us to estimate how much longer subjects
should remain on their current non-suppressive therapy in order to maximize their
expected CD4 T cell count 8 months later, given how long they have already been on
non-suppressive therapy and their current CD4 T cell count. Among individuals who
have not already switched, the effect of each additional month waiting to switch therapy
is β 1 + β 4 CD 4( j ) + β 5 j .
At any given time point, this expression provides an optimal static future
treatment regimen. When this expression is negative, each additional month waiting to
switch will lead to depletion of CD4 T cells, suggesting that an individual should be
switched immediately. When the expression is positive, waiting to switch will result in a
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gain in CD4 T-cells, suggesting that the patient should be maintained on his current
regimen.
The optimal future static treatment regimen estimated by HA-MSM in turn
suggests an interesting dynamic treatment regimen. Recall that a dynamic treatment
regimen is a rule or function that gives a recommended treatment decision at each time
point, based on patient characteristics measured up till the time point. The dynamic
treatment regimen identified by HA-MSM consists of following, at each time point, the
first action of an individual's optimal static future treatment regimen at that time point. At
subsequent time points, the optimal static future treatment regimen can then be updated in
response to changes in covariates and treatment history.
RESULTS: WHEN TO SWITCH ANTIRETROVIRAL THERAPY
In our example, we identified from SCOPE a total of 100 patients who
experienced loss of viral suppression on antiretroviral therapy and who had a CD4 T cell
count measured 8 months later. Since a patient could contribute more than one episode of
loss of suppression, we evaluated a total of 116 unique treatment episodes. Most patients
had been on multiple treatment regimens prior to inclusion in our analysis.
The median time to switch after onset of failure was 6 months. Tables 1 and 2 describe
the sample at time of confirmed virologic failure.
Cross-validated data-adaptive logistic regression (using the Deletion/
Substitution/ Addition algorithm (10)) was used to model the probability of switching
therapy at each time point (the treatment mechanism) based on 40 candidate covariates
(this included all covariates in tables 1 and 2, the time elapsed since loss of suppression,
and plasma HIV RNA levels, defined as below of above the assay limit). The resulting fit
of the treatment mechanism is shown in table 3.
The following standard MSM were used to estimate:
1. The marginal effect of time until switching therapy (c) on CD4 T cell count 8
months after loss of suppression (Y(8)): E (Yc (8)) = β 0 + β 1c
2. The effect of time until switching therapy on CD4 T cell count 8 months after loss
of suppression (baseline), conditional on CD4 T cell count at baseline (CD4(0)):
E (Yc (8) | CD 4(0)) = β 0 + β 1c + β 2 CD 4(0) + β 3 c × CD 4(0)
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Table 4 shows the estimates of causal effects based on these models, as well as
the corresponding non-causal associations (unadjusted for confounding). The MSM
results suggest that, while waiting to switch therapy is generally associated with a loss of
CD4 T cells (9.9 cells/month), waiting to switch is not detrimental among patients with
high CD4 T cell counts (> 218 cells) at the time of virologic failure. The discrepancy
between the causal coefficients, as estimated using MSM, and the non-causal associations
(-9.9 vs. 4.9, -13.1 vs. -9.5) suggests the presence of significant time-dependent
confounding.
At each time point, HA-MSM were used to estimate the effect of additional time
until switching therapy among patients who remained on their original therapy,
conditional on current CD4 T cell count. Nineteen individuals achieved re-suppression of
the virus during follow-up despite remaining on the same therapy (an indicator that
virologic failure was not due to resistance). As we aimed to estimate the effect of waiting
to switch therapy among individuals with loss of viral suppression due to the presence of
resistant virus, HA-MSM were fit only among those individuals with no history of resuppression (I(Supp=0)). Our HA-MSM aimed to replicate the results of a randomized
trial in which individuals currently on a non-suppressive therapy regimen and with no
history of re-suppression on this regimen were assigned to switch to a new therapy at a
random time in the future.
Two sets of HA-MSM analyses were conducted. In the first, the following model
was assumed, and separate coefficients were estimated for each time point j.
E (Y A( j −1) c ( j ) ( j + 8) | A( j − 1) = 1, CD 4( j ))
= I ( A( j − 1) = 1 × I ( Supp = 0) × ( β 0 + β 1c( j ) + β 2 CD 4( j ) + β 3 c( j ) × CD 4( j ))

Based on the resulting coefficient estimates for the first nine months (j=0,..,8), figure 1
plots the estimated effect of each additional month waiting to switch therapy for three
current CD4 T cell counts.
Figure 1 suggests that the effect of additional time until switching differs
depending on the amount of time an individual has already spent on non-suppressive
therapy, as well as on the individual's current CD4 T cell count. Specifically, in the
months immediately subsequent to loss of virologic suppression, waiting to switch
therapy appears beneficial among individuals with high current CD4 T cell counts, but
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detrimental in those with low CD4 T cell counts. In contrast, among the population that
have already spent at least five months on their current non-suppressive therapy,
additional time waiting to switch has a negligible effect on future CD4 T cell count,
regardless of an individual's current CD4 T cell count. This effect modification may be
due in part to the fact that the population remaining on non-suppressive therapy for at
least five months is a different population than the original group failing therapy; they are
likely to have remained on non-suppressive therapy precisely because they were better
able to tolerate it.
In the second set of analyses, a single model was fit for the first nine time points
(j=0,..,8), now assuming common parameters across time and including time spent on
non-suppressive therapy as a covariate in the model:
E (Y A( j −1),c ( j ) ( j + 8) | ( A( j − 1) = 1, CD 4( j )) = I ( A( j − 1) = 1) × I ( Supp = 0) ×
( β 0 + β 1c( j ) + β 2 CD 4( j ) + β 4 c( j ) × CD 4( j ) + β 5 c( j ) × j + β 6 c( j ) × CD 4( j ) × j )

Using this common model, the estimated effect of each additional month until switching
therapy is

β 1 + β 4 CD 4( j ) + β 5 j + β 6 CD 4( j ) × j
= −10.4 + 0.05 × CD 4( j ) + 1.9 × j − 0.01 × CD 4( j ) × j
Table 5 shows the estimates of causal effect of switching based on this model
(plotted for three CD4 T cell values in figure 2). This fit provides us with a decision rule
for when to switch therapy; when this expression is negative, switch therapy
immediately. When this expression is positive, wait until the next month, then re-evaluate
the expression based on current CD4 T cell count and elapsed time.
DISCUSSION
The HA-MSM presented in this paper represent an important generalization of
MSM methodology. MSM are well-established as powerful tools for causal inference,
particularly in the setting of longitudinal data. In this article we have introduced an
extension of MSM to identify and estimate time-dependent causal effect modification.
We have further illustrated how HA-MSM make possible the identification of a specific
type of dynamic treatment regimen. The dynamic treatment regimens identified by HA-
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MSM will be most appropriate as candidates for future clinical trials when they include
all major effect modifiers of the exposure of interest (1).
Alternative statistical methods currently available for identifying and evaluating
dynamic treatment regimens, such as Structural Nested Mean Models (SNMM) and Gcomputation (11-13), require substantial programming effort to implement, perhaps
explaining the paucity of epidemiologic research aimed at estimating dynamic treatment
regimens. In contrast, as illustrated in this paper, HA-MSM can be implemented using
standard software. In addition, SNMM and G-computation both identify dynamic
treatment regimens aimed at optimizing an outcome at a fixed time-point. In contrast, in
the example presented, HA-MSM were used to identify a dynamic treatment regimen
aimed at optimizing a continuously changing outcome (CD4 T cell count 8 months in the
future). In many applications, optimizing such a "moving" outcome, rather than an
outcome at a fixed time point, may indeed be the researchers’ goal.
In conclusion, HA-MSM identify treatment decision rules based on timedependent covariates that are expected to optimize patient outcome. Identification of such
dynamic treatment regimens is a crucial application in the medical sciences, in addition to
other fields that rely on dynamic decision-making. We anticipate that these models will
prove a useful tool in multiple fields of applied research.
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TABLE 1. Characteristics of sample at time of failure (continuous variables).1
Characteristic
Plasma HIV RNA level
CD4 T cell count
CD8 T cell count
Percent Average Adherence (self report)
Year Diagnosed with HIV
Age
Year of first antiretroviral treatment
Peak HIV RNA level (lab records)
Nadir CD4 T cell count (lab records)
Number of PI2 drugs experienced
Number of NRTI3 drugs experienced
Number of NNRTI4 drugs experienced

Median Mean
3rd Quartile Missing
1st Quartile
365.5
4317 34190
24940
0
175.5
261.5
321
428.8
0
726.8
1022
1168
1497
0
100
100
92.36
100
0
1986
1989
1989
1993
2
44.2
50.5
49.9
55.5
0
1991
1996
1995
1997
0
46020 177500 242300
381200
0
36.25
72.5
118.3
165
0
2
3
3.241
4
0
4
5
4.819
6
0
0
1 0.9138
1
0

1

Among 100 individuals (116 episodes) with a know time of viral failure, and follow-up for at least 8
months following time of failure.
2
Protease inhibitor
3
Nucleoside reverse transcriptase inhibitor
4
Non-nucleoside reverse transcriptase inhibitor
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TABLE 2. Characteristics of sample at time of failure (Categorical Variables).5
Characteristc
Treatment history
Enfuvurtide
Tenofovir
Lamivudine
Mono/dual ART6
Current Treatment
Protease inhibitor
Nucleoside reverse transcriptase inhibitor
Non-nucleoside reverse transcriptase inhibitor
Lab Frequency
Most Recent HIV RNA level > than one month prior
Most Recent CD4 T cell count > than one month prior
Subject Characteristics
History of intravenous drug use
Male
Sexual orientation "Man who has sex with men"
Homeless within past year
Current diagnosis with an opportunistic disease
Self-identified HIV risk group
Man having sex with men
Intravenous drug use ever
Heterosexual Intercourse
Other
Race/ethnicity
White
African-American/Black
Latino/Hispanic/ Mexican-American
Other
Crack use (past 4 months)
Every day
Once a week
Once a month
Less than once a month
Never
Methamphetamine use (past 4 months)
Once a week
Once a month
Less than once a month
Never

N (%)

Missing
0

8 (7%)
41 (35%)
115 (99%)
57 (49%)
0
87 (75%)
113 (97%)
22 (19%)
0
49 (42%)
42 (36%
43 (37%)
100 (86%)
79 (69%)
6 (5%)
25 (22%)

0
0
1
0
0
0

79 (68%)
22 (19%)
8 (7%)
7 (6%)
0
51 (44%)
35 (30%)
17 (15%)
13 (11%)
1
3 (3%)
6 (5%)
3 (3%)
7 (6%)
96 (83%)
1
2 (2%)
4 (3%)
3 (3%)
106 (92%)

5

Among 100 individuals (116 episodes) with a know time of viral failure, and follow-up for at least 8
months following time of failure
6
ART=Antiretroviral treatment
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Alcohol Use (past 4 months)
At least once a day
Nearly every Day
3-4 times a week
1-2 times a week
2 or 3 times total
Once
Never
Education (highest year of school completed)
Grades 7-11
High School/GED
Some College
4 Years College/BS/BA
Some/Completed Graduate School
Income (yearly household)
<=$6000
$6001-$12,000
$12,001-$18,000
$18,001-$24,000
$24,001-$30,000
$30,001-$36,000
$36,001-$75,000
>$75,000

1
10 (9%)
6 (5%)
7 (6%)
26 (23%)
14 (12%)
12 (10%)
40 (35%)
0
16 (14%)
24 (21%)
46 (40%)
19 (16%)
11 (9%)
0
5 (4%)
50 (43%)
20 (17%)
14 (12%)
2 (2%)
4 (3%)
13 (11%)
8 (7%)
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TABLE 3. Odds ratios for switching treatment based on data-adaptive fit of
treatment mechanism.7 8
Covariate
Current diagnosis with an opportunistic disease
Number of protease inhibitor drugs experienced
Most recent HIV RNA level undetectable
Percent average adherence (per 10%)
Most recent CD4 T cell count (per 100 CD4 T cells)
Nadir CD4 T cell count (per 100 CD4 T cells)
Most recent HIV RNA level more than one month prior
Age (per 5 years)

Odds Ratio
1.22
1.11
0.44
0.92
0.92
1.05
0.90
0.90

7

Note: Variables for treatment mechanism selected among larger sample of non-suppressed in SCOPE
cohort: 255 people, 368 episodes, including people with unknown loss of suppression time and missing
outcome. The coefficients on the selected model (corresponding to the Odds Ratios reported here) were
then refit on the population with known loss of suppression time.
8
Note: Standard errors and P-values not shown, to emphasize that role of the treatment mechanism in
construction of weights, rather than for the purposes of causal interpretation.

http://biostats.bepress.com/ucbbiostat/paper199

TABLE 4. Non-causal associations and estimated causal effects of time until switching
therapy on CD4 T Cell Count 8 months after loss of suppression.9 10
Coefficient
95% CI11 12
Associations for Each Additional Month Until Switching Therapy
4.9
-6.3, 16.8
Unadjusted Association:
E(Y(8)|C=c)
Multivariable Regression:
E(Y(8)|CD4(t=0),C=c)

-9.5
0.05 * CD4(t=0)

-17.7, -1.3
0.03, 0.08

Causal Effects of Each Additional Month Until Switching Therapy
Standard MSM:
- 9.9
-21.1, 2.9
E(Yc (8))
Conditional Standard MSM:
E(Yc (8)|CD4(t=0))

-13.1 c
0.06 * CD4(t=0)

-22.5, -4.8
0.03, 0.09

9

“C” and “c” denote, respectively, the observed and counterfactual number of months after baseline (viral
failure) of exposure to original non-suppressive therapy
10
CD4 (t=0) denotes observed CD4 T cell count at baseline (time of viral failure).
11
Based on 100 Bootstrap samples
12
CI=Confidence interval
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TABLE 5. Coefficients from HA-MSM model for first 9 time points (j=0,..,8).13
Estimated effect of each additional month until switching therapy, given current CD4 T
cell count (CD4(j)) and elapsed time since failure occurred (j).
Coefficient
-10.4
0.05 x CD4(j)
1.9 x j
- 0.01 x CD4(j) x j

95% CI14 15
-18.5, -4.0
0.03, 0.08
-0.03, 3.4
-0.02, -0.003

13

Estimated among people who have not yet switched therapy and have not re-suppressed the virus.
Based on 100 Bootstrap samples
15
CI = Confidence Interval
14
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FIGURE 1. Separate HA-MSM fit at each of first 9 time points.16
Effect of each additional month until switching
on CD4 T cell count 8 months later

Difference in CD4 T cell count per
month until switch
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Estimated among people who have not yet switched therapy and have not re-suppressed the virus.
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FIGURE 2: Single HA-MSM fit for first 9 time points.17
Effect of each additional month until switching
on CD4 T cell count 8 months later

Difference in CD4 T cell count per
month until switch
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Estimated among people who have not yet switched therapy and have not re-suppressed the virus.
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